par Sculier, Jean-Paul ;Paesmans, Marianne ;Bureau, Gérard;Dabouis, Gérard;Libert, Philippe ;Vandermoten, Guy;Van Cutsem, O;Berchier, M.C.;Ries, Fernand ;Michel, Jeffrey;Sergysels, Roger ;Mommen, Paul;Klastersky, Jean
Référence Revue des maladies respiratoires, 11, 3, page (257-261)
Publication Publié, 1994
Référence Revue des maladies respiratoires, 11, 3, page (257-261)
Publication Publié, 1994
Article révisé par les pairs
Résumé : | The administration of multiple cytostatic drugs on a weekly basis has been proposed as a new intensive chemotherapy modality for small-cell lung cancer. The European Lung Cancer Working Party has conducted a randomized trial comparing to a standard regimen (cyclophosphamide + adriamycine + etoposide given at the cycle beginning) a weekly chemotherapy with 7 active drugs (cyclophosphamide + adriamycine + etoposide on day 1; cisplatin + vindesine on day 8; methotrexate + vincristine on day 15). A total of 215 eligible patients have been registered. There has been no significant difference between the 2 arms for response and for survival. The total relative dose-intensity has been lower in the weekly chemotherapy arm. This approach has failed to improve current results. |